Stanford University genetics professor Dr. Stanley Cohen paid $29.2 million to settle a lawsuit over misleading claims he made about Nuredis Inc., his now-dissolved biotechnology company.

A prominent genetics professor at Stanford University in the US ... claimed he misled them whist persuading them to invest $20 million in the biotech, set up to develop a candidate therapy for ...

Why it matters: Xaira is the landing spot for CEO Marc Tessier-Lavigne, the former Genentech chief scientific officer and Denali Therapeutics co-founder who last year resigned as Stanford ...

The Stanford Biotechnology Business & Finance Group ... in exploring careers in biotechnology business, management, and investment. This member driven group will host invited speakers from local ...

The long-time Stanford University and University ... When Pfizer finally decided to invest, it did so heavily and with a twist of biotech culture. The New York-based pharma would model its ...

Strong financial positions reduce risk in biotech investing, prioritizing firms with both current and pipeline drugs. Vertex shows diversified drug development in chronic diseases, underscoring ...